Dulaglutide vs Semaglutide
A side-by-side research comparison of Dulaglutide and Semaglutide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Dulaglutide | Semaglutide |
|---|---|---|
| Full name | Dulaglutide (Trulicity) | Semaglutide (GLP-1 Receptor Agonist) |
| Category | Weight Management | Weight Management |
| Status | Prescription medication (FDA-approved) | FDA Approved |
| Mechanism | Activates GLP-1 receptors in pancreatic beta cells (enhancing glucose-dependent insulin secretion), the hypothalamus (reducing appetite), and the GI tract (slowing gastric emptying). The Fc fusion extends half-life to ~5 days. | Binds GLP-1 receptors in the pancreas to stimulate insulin secretion, in the brain to reduce appetite, and in the GI tract to slow gastric emptying. 94% homology to native GLP-1. |
| Molecular weight | ~63,000 Da | 4,114 Da |
| Half-life | ~5 days (supports weekly dosing) | 7 days (168 hours) |
| Bioavailability | ~65% subcutaneous | High (SubQ ~89%), Moderate (oral ~1% with SNAC) |
| Typical dose | 0.75 mg - 4.5 mg once weekly | 0.25 mg → titrate up to 2.4 mg |
| Frequency | Once weekly | Once weekly |
| Route | Subcutaneous injection (pre-filled pen) | Subcutaneous injection |
Dulaglutide reported benefits
- Significant weight loss (3-5% at standard doses)
- Improved glycemic control
- Reduced cardiovascular events (REWIND trial)
- Once-weekly convenience
- Appetite suppression
Semaglutide reported benefits
- Significant weight loss (15-17%)
- Improved glycemic control
- Cardiovascular risk reduction
- Reduced food cravings
- Lower HbA1c
Related comparisons
Research and educational reference only. Not medical advice.